Skip to main content

Advertisement

SpringerLink
Log in

Treatment strategies are more important than drugs in the management of rheumatoid arthritis

  • Perspectives in Rheumatology
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The treatment of inflammatory arthritides has been changed dramatically in the past two decades with the introduction of the biological (b) disease-modifying anti-rheumatic drugs (DMARDs) as well as the targeting synthetic (ts) DMARDs that can be used as monotherapy or in combination with conventional synthetic (cs) DMARDs. The concept of treat to target (T2T) and tight control monitoring of disease activity represents a therapeutic paradigm of modern rheumatology. In rheumatoid arthritis (RA), this treatment approach has proven to be effective in many clinical trials and is now a well-established approach. The most common treatment strategies rely on the combination of csDMARDs (mainly methotrexate, sulfasalazine and hydroxychloroquine). This comes from different studies which compare the outcomes of combination therapies versus csDMARD monotherapy or versus methotrexate plus biologics in early RA patients. Here, we review the literature of the most important T2T studies for RA patients. The results showed that a tight control strategy appears to be more important than a specific drug to control RA. T2T approach aiming for remission or low disease activity can be achieved in early RA patients using less expensive drugs in comparison to newer drugs and this may need to be recognised in the future recommendations for the management of RA.

Key Points

• Tight-control and treat-to-target (T2T) strategies are the cornerstone in achieving remission or low disease activity in rheumatoid arthritis (RA)

• A plethora of clinical trials has confirmed the efficacy of csDMARDs when the tight-control and T2T strategies are applied

• T2T and tight-control strategies are a less expensive option in comparison to newer drugs and may be recognised in the future recommendations for the management of RA.

• Treatment decisions and strategies are more important than just the drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smolen JS, Landewe R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://doi.org/10.1136/annrheumdis-2016-210715

    Article  PubMed  Google Scholar 

  2. Drosos AA, Psychos D, Andonopoulos AP, Stefanaki-Nikou S, Tsianos EB, Moutsopoulos HM (1990) Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up. Clin Rheumatol 9:333–341. https://doi.org/10.1007/bf02114393

    Article  CAS  PubMed  Google Scholar 

  3. Drosos AA, Karantanas AH, Psychos D, Tsampoulas C, Moutsopoulos HM (1990) Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis? Clin Rheumatol 9:342–345. https://doi.org/10.1007/bf02114394

    Article  CAS  PubMed  Google Scholar 

  4. Drosos AA, Pelechas E, Voulgari PV (2019) Rheumatoid arthritis treatment. A Back to the drawing board project or high expectations for low unmet needs? J Clin Med 8(8):E1237. https://doi.org/10.3390/jcm8081237

    Article  CAS  PubMed  Google Scholar 

  5. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA (2019) Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum 48:597–602. https://doi.org/10.1016/j.semarthrit.2018.06.003

    Article  PubMed  Google Scholar 

  6. Sokka T, Pincus T (2009) Rheumatoid arthritis: strategy more important than agent. Lancet 374:430–432. https://doi.org/10.1016/S0140-6736(09)61432-X

    Article  PubMed  Google Scholar 

  7. Atar D, Birkeland KI, Uhlig T (2010) “Treat to target”: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. Ann Rheum Dis 69:629–630. https://doi.org/10.1136/ard.2010.128462

    Article  PubMed  Google Scholar 

  8. Cooper-Dehoff RM, Gong Y, Handberg EM et al (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304:61–68. https://doi.org/10.1001/jama.2010.884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Haagsma CJ, Van Riel PL, De Rooij DJ et al (1994) Combination of methotrexate and Sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to suplhasalazine therapy. Br J Rheumatol 33:1049–1055. https://doi.org/10.1093/rheumatology/33.11.1049

    Article  CAS  PubMed  Google Scholar 

  10. Haagsma CJ, Van Riel PL, De Jong AJ, Van De Putte LB (1997) Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52-week clinical trial. Br J Rheumatol 36:1082–1088. https://doi.org/10.1093/rheumatology/36.10.1082

    Article  CAS  PubMed  Google Scholar 

  11. Boers M, Verhoeven AC, Markusse HM, van de Laar M, Westhovens R, van Denderen J, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van den Brink H, Schouten HJ, van der Heijde D, Boonen A, van der Linden S (1997) Randomised comparison of combined step-down prednisolone, methotrexate and Sulphasalazine with Sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318. https://doi.org/10.1016/S0140-6736(97)01300-7

    Article  CAS  PubMed  Google Scholar 

  12. Landewe RB, Boers M, Verhoeven AC et al (2002) COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46:347–356. https://doi.org/10.1002/art.10083

    Article  CAS  PubMed  Google Scholar 

  13. Van Tuyl LH, Boers M, Lems WF et al (2010) Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 69:807–812. https://doi.org/10.1136/ard.2009.108027

    Article  PubMed  Google Scholar 

  14. Poppelaars PB, Van Tuyl LHD, Boers M (2019) Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. Ann Rheum Dis 78:586–589. https://doi.org/10.1136/annrheumdis-2018-214618

    Article  PubMed  Google Scholar 

  15. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'Dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64:640–647. https://doi.org/10.1002/acr.21649

    Article  Google Scholar 

  16. Prevoo ML, Van ‘T Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48. https://doi.org/10.1002/art.1780380107

    Article  CAS  PubMed  Google Scholar 

  17. Mottonen T, Hannonen P, Leirisalo-Repo M, FIN-RACo trial group et al (1999) Comparison of combination therapy with single-drup therapy in early rheumatoid arthritis: a randomised trial. Lancet 353:1568–1573. https://doi.org/10.1016/s0140-6736(98)08513-4

    Article  CAS  PubMed  Google Scholar 

  18. Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group (2009) The good initial response to therapy with a combination of traditional diseases modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 60:1222–1231. https://doi.org/10.1002/art.24447

    Article  PubMed  Google Scholar 

  19. Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpää S, Hannonen P, Leirisalo-Repo M, Blåfield H, Puolakka K, Karjalainen A, Möttönen T, FIN-RACo Trial Group (2010) FIN-RACo trial group Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 12(3):R122. https://doi.org/10.1186/ar3060

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T, NEO-RACo Study Group (2013) NEO-RACo study group Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 72(6):851–857. https://doi.org/10.1136/annrheumdis-2012-201365

    Article  CAS  PubMed  Google Scholar 

  21. Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M, NEO-RACo Study Group (2014) Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis 73(11):1954–1961. https://doi.org/10.1136/annrheumdis-2013-203497

    Article  CAS  PubMed  Google Scholar 

  22. Rantalaiho V, Sandström T, Koski J, Hannonen P, Möttönen T, Kaipiainen-Seppänen O, Yli-Kerttula T, Kauppi MJ, Uutela T, Malmi T, Julkunen H, Laasonen L, Kautiainen H, Leirisalo-Repo M, NEO-RACo study group (2019) Early targeted combination treatment with conventional synthetic disease-modifying Antirheumatic drugs and long-term outcomes in rheumatoid arthritis: ten-year follow-up results of a randomized clinical trial. Arthritis Care Res (Hoboken) 71(11):1450–1458. https://doi.org/10.1002/acr.23782

    Article  CAS  Google Scholar 

  23. Rantalaiho V, Kautiainen H, Jarvenpaa S et al (2014) Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial. J Rheumatol 41:2379–2385. https://doi.org/10.3899/jrheum.140267

    Article  PubMed  Google Scholar 

  24. Fransen J, Moens HB, Speyer I, Van Riel PL (2005) Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicenter, cluster randomised controlled trial. Ann Rheum Dis 64:1294–1298. https://doi.org/10.1136/ard.2004.030924

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269. https://doi.org/10.1016/S0140-6736(04)16676-2

    Article  PubMed  Google Scholar 

  26. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381–3390. https://doi.org/10.1002/art.21405

    Article  CAS  PubMed  Google Scholar 

  27. Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Allaart CF et al (2007) Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis 66:1227–1232. https://doi.org/10.1136/ard.2006.068296

    Article  PubMed  PubMed Central  Google Scholar 

  28. Verstappen SM, Jacobs JW, Van Der Veen MJ et al (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66:1443–1449. https://doi.org/10.1136/ard.2007.071092

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hetland ML, Stengaard-Pedersen K, Junker P et al (2008) Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 67:815–822. https://doi.org/10.1136/ard.2007.076307

    Article  CAS  PubMed  Google Scholar 

  30. Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon A, Porter DR (2008) Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 58:1310–1317. https://doi.org/10.1002/art.23449

    Article  CAS  PubMed  Google Scholar 

  31. Moreland LW, O’Dell JR, Paulus HE et al (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive erheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum 64:824–835

    Article  Google Scholar 

  32. Soubrier M, Puechal X, Sibilia J et al (2009) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 48:1429–1434. https://doi.org/10.1093/rheumatology/kep261

    Article  CAS  Google Scholar 

  33. O’Dell JR, Mikuls TR, Taylor TH et al (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369:307–318. https://doi.org/10.1056/NEJMoa1303006

    Article  CAS  PubMed  Google Scholar 

  34. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Cöster L, Waltbrand E, Zickert A, Theander J, Thörner A, Hellström H, Teleman A, Dackhammar C, Akre F, Forslind K, Ljung L, Oding R, Chatzidionysiou A, Wörnert M, Bratt J (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 374:459–466. https://doi.org/10.1016/S0140-6736(09)60944-2

    Article  CAS  PubMed  Google Scholar 

  35. Van Vollenhoven RF, Geborek P, Forslind K et al (2012) Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2-year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379:1712–1720. https://doi.org/10.1016/S0140-6736(12)60027-0

    Article  CAS  PubMed  Google Scholar 

  36. Verhoeven MMA, De Hair MJH, Tekstra J et al (2019) Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials. Ann Rheum Dis 78:1333–1338. https://doi.org/10.1136/annrheumdis-2019-215304

    Article  CAS  PubMed  Google Scholar 

  37. Schipper LG, Van Hulst LT, Grol R et al (2010) Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 49:2154–2164. https://doi.org/10.1093/rheumatology/keq195

    Article  Google Scholar 

  38. Kuriya B, Xiong J, Boire G, Haraoui B, Hitchon C, Pope J, Thorne JC, Tin D, Keystone EC, Bykerk V, CATCH Investigators (2014) Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis – results from the Canadian Early Arthritis Cohort (CATCH). J Rheumatol 41:2161–2166. https://doi.org/10.3899/jrheum.140137

    Article  PubMed  Google Scholar 

  39. Littlejohn G, Roberts L, Bird P et al (2015) Patients with rheumatoid arthritis in the Australian OPAL cohort show significant improvement in disease activity over 5 years: a multicenter observational study. J Rheumatol 42:1603–1609. https://doi.org/10.3899/jrheum.141575

    Article  CAS  PubMed  Google Scholar 

  40. Sokka T, Haugeberg G, Asikainen J, Widding Hansen IJ, Kokko A, Rannio T, Soldal DM, Hannonen P (2013) Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. Clin Exp Rheumatol 31:409–414

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece

    Alexandros A. Drosos, Eleftherios Pelechas & Paraskevi V. Voulgari

Authors
  1. Alexandros A. Drosos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleftherios Pelechas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paraskevi V. Voulgari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandros A. Drosos.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Drosos, A.A., Pelechas, E. & Voulgari, P.V. Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clin Rheumatol 39, 1363–1368 (2020). https://doi.org/10.1007/s10067-020-05001-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05001-x

Keywords

Search

Navigation